|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||29.39 / 47.82|
A Mother's Day message to Wall Street. Why are women and mom's still lagging when it comes to leadership and pay parity. Yes. it's 2018. Watch videos, listen to podcasts.
The EpiPen maker saw a 19% drop in North America net sales due in part to lower sales of branded products.
While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.
The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.
The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.
Three posters highlight Mylan's rigorous Glatiramer Acetate development program
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.
The drug company generates about 60% of revenue outside the U.S.
While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.
The pharmaceutical firm will conduct its investor day in New York City on April 11.
- Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S., including recently announced Symfi Lo™ and Cimduo™
- Mitomycin for Injection is available to Mylan's hospital and other institutional customers -
Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.
A massive price-fixing lawsuit brought by 45 states against a group of generic drug producers as well as a changing of the guard at the Food and Drug Administration may lead to changes in the generic drug sector.
Here's what you need to know now for Tuesday, March 6.
Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.
Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.
This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.
- FDA recently approved Symfi Lo™, a three-drug single-tablet antiretroviral (ARV) regimen, and Cimduo™, a double combination, for HIV treatment
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.